Join the Thyroid Cancer group to help and get support from people like you.
Thyroid Cancer News
Related terms: Anaplastic thyroid cancer
New Hope Against a Rare, Aggressive Form of Thyroid Cancer
MONDAY, Oct. 28, 2024 – Most thyroid cancers are slow-moving and, if caught early, curable. But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) – a rare and...
FDA Grants Traditional Approval to Retevmo (selpercatinib) for Medullary Thyroid Cancer with a RET Mutation
On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with...
Melanoma Risk Increased After Radioactive Iodine Treatment for Primary Thyroid Cancer
THURSDAY, Sept. 26, 2024 – Patients with primary thyroid cancer who receive radioactive iodine therapy have an elevated risk for melanoma and other nonkeratinocyte skin cancers when limiting the...
Study Looks at Impact of Peritoneal Dialysis on Thyroid Function
MONDAY, Sept. 23, 2024 – Patients undergoing peritoneal dialysis (PD) have significantly higher thyroxine (T4) concentrations than hemodialysis (HD) patients and higher free T4 (FT4) concentrations...
FDA Grants Accelerated Approval to Retevmo (selpercatinib) for Pediatric Patients Two Years and Older with RET-Altered Metastatic Thyroid Cancer or Solid Tumors
On May 29, 2024, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for pediatric patients two years of age and older with the following: ...
FDA Grants Traditional Approval for Retevmo (selpercatinib) for RET Fusion-Positive Thyroid Cancer
On June 12, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with...
GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer
WEDNESDAY, April 24, 2024 – Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online...
Microwave Ablation Feasible for T1N0M0 Papillary Thyroid Carcinoma
FRIDAY, April 12, 2024 – For patients with multifocal papillary thyroid carcinoma (PTC), the rates of progression-free survival (PFS) do not differ between microwave ablation (MWA) and surgical...
Ozempic, Wegovy Won't Boost Thyroid Cancer Risk: Study
WEDNESDAY, April 10, 2024 – Wegovy, Ozempic and other drugs known as GLP-1 analogues have become wildly popular for controlling diabetes and helping folks lose weight. There were concerns that...
Microwave Treatment Could Be an Advance Against Thyroid Tumors
WEDNESDAY, April 3, 2024 – Microwaves could offer an alternative to surgery for some people with thyroid cancer, a new study suggests. Microwave ablation, which uses heat to destroy tumors, more...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 17, 2021-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) approved Cabometyx® (cabozantinib) for the treatment ...
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
South San Francisco, CA – December 1, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Retevmo (selpercatinib) for Patients with Advanced RET-Driven Lung and Thyroid Cancers
INDIANAPOLIS, May 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Retevmo™ (selpercatinib, 40 mg & 80 mg capsules), ...
FDA Approves Tafinlar + Mekinist for the Treatment of BRAF-Positive Anaplastic Thyroid Cancer
May 4, 2018 – The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot...
FDA Approves Lenvima (lenvatinib) for Differentiated Thyroid Cancer
February 13, 2015 – The U.S. Food and Drug Administration today granted approval to Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer (DTC) whose disease...